Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Annette Wundes"'
Autor:
Annette Wundes, Sibyl Wray, Ralf Gold, Barry A. Singer, Elzbieta Jasinska, Tjalf Ziemssen, Jerome de Seze, Pavle Repovic, Hailu Chen, Jerome Hanna, Jordan Messer, Catherine Miller, Robert T. Naismith
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Diroximel fumarate (DRF) is a novel oral fumarate approved for relapsing forms of multiple sclerosis (MS). DRF demonstrated significantly improved gastrointestinal (GI) tolerability versus dimethyl fumarate (DMF) with fewer days of Indivi
Externí odkaz:
https://doaj.org/article/7dcf8de81cf441938990675a654ee297
Publikováno v:
Multiple Sclerosis International, Vol 2014 (2014)
Pregnancy in multiple sclerosis (MS) is considered safe for both the woman and the child. Nevertheless, pregnancy issues in MS are complex both from a patient’s and a provider’s perspective. In an anonymous survey, 28 healthcare providers in the
Externí odkaz:
https://doaj.org/article/bbe8194851a741a2a74d18c704158c79
Autor:
Maria Houtchens, Annette Wundes, Benjamin Osborne, Ivan Bozin, Filipe Branco, Hailu Chen, Sarah England, Nancy Gerber, Seth Levin, Xiaochen Lin, Matthew Scaramozza, Kerstin Hellwig
Publikováno v:
Tuesday, April 25.
Autor:
Annette Wundes, John Lindsey, Hailu Chen, Matthew Scaramozza, Filipe Branco, Wanda Castro-Borrero, Sai Shankar, Robert Naismith
Publikováno v:
Tuesday, April 25.
Autor:
Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L. Arnold, Jelena Drulovic, Elzbieta Jasinska, James D. Bowen, Donald Negroski, Robert T. Naismith, Samuel F. Hunter, Mark Gudesblatt, Hailu Chen, Jennifer Lyons, Sai L. Shankar, Shivani Kapadia, Jason P. Mendoza, Barry A. Singer
Publikováno v:
Advances in Therapy. 39:1810-1831
Autor:
Anna L. Kratz, Mark P. Jensen, Annette Wundes, Charles H. Bombardier, Gloria von Geldern, Peiqing Qian, Dawn M. Ehde, Daniel Whibley, Kevin N. Alschuler
Publikováno v:
Journal of Neurology. 269:2560-2572
Little is known about quality of life (QOL) at the time of multiple sclerosis (MS) or clinically isolated syndrome (CIS) diagnosis and how it evolves in the critical adjustment period immediately following a new diagnosis. To (1) describe QOL traject
Autor:
Robert T. Naismith, Elzbieta Jasinska, Hailu Chen, Jennifer L. Lyons, Maria Lopez-Bresnahan, Annette Wundes, Tjalf Ziemssen, David Rezendes, Jerry S. Wolinsky, Anthony Lembo, Richard Leigh-Pemberton, Krzysztof Selmaj, Catherine Miller, Ilda Bidollari, Jerome Hanna, Mark S. Freedman
Publikováno v:
CNS Drugs
Background Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF). DRF 462 mg and DM
Autor:
Paul, Kamudoni, Dagmar, Amtmann, Jeffrey, Johns, Karon F, Cook, Rana, Salem, Sam, Salek, Jana, Raab, Rod, Middleton, Pavle, Repovic, Kevin N, Alschuler, Gloria, von Geldern, Annette, Wundes, Amy, Barrett, Oyebimpe, Olayinka-Amao, Christian, Henke
A valid, sensitive patient-reported outcome (PRO) measure of physical function (PF) for people with multiple sclerosis (MS) would have substantial value in routine care and clinical research. We now describe development of the PROMISnq Short Form v2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c28ec14aa440065ee20cd749ce718ea5
https://cronfa.swan.ac.uk/Record/cronfa61485/Download/61485__25534__bcc55f6fae9144638366ab7826c49df0.pdf
https://cronfa.swan.ac.uk/Record/cronfa61485/Download/61485__25534__bcc55f6fae9144638366ab7826c49df0.pdf
Autor:
Lili Yang, Hailu Chen, Douglas L. Arnold, Catherine Miller, David Rezendes, Boris Kandinov, Christopher LaGanke, Jerry S. Wolinsky, Mark S. Freedman, Maria Lopez-Bresnahan, Narinder Nangia, Dragana Obradovic, Jerome Hanna, Tjalf Ziemssen, Annette Wundes, Robert T. Naismith, Richard Leigh-Pemberton, Ilda Bidollari, Mark Gudesblatt, Shifang Liu
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Diroximel fumarate (DRF) is a novel oral fumarate for patients with relapsing–remitting multiple sclerosis (RRMS). DRF and the approved drug dimethyl fumarate yield bioequivalent exposure to the active metabolite monomethyl fumarate; th